Alina, was then working as a teacher at a secondary school in Kajang, Selangor. Initially, she thought her condition was due to work-related stress.

The myasthenia gravis treatment market is anticipated to grow at a CAGR of 7.14% from US$1.973 billion in 2025 to US$2.785 billion by 2030.” NEW YORK, NY, UNITED STATES, April 24, 2025 ...

MG-ADL scores improved, indicating enhanced daily functioning for patients with myasthenia gravis. Limitations include potential coding errors, selection biases, and missing clinical data ...

"Elraglusib with chemotherapy and immune priming represents a novel sequential therapy approach to treat advanced salivary cancers. We were encouraged by the response rate among the non-Adenoid ...

Ultomiris (ravulizumab-cwvz) is a brand-name infusion prescribed for myasthenia gravis. This article covers topics such as side effects, dosage, and how Ultomiris works. Ultomiris is an ...

Nicholas J. Silvestri, MD, describes how this year’s AAN meeting highlighted significant advances in myasthenia gravis, including improved diagnostics through cell-based assays that enhance ...

Introduction: Thymoma-associated myasthenia gravis (TAMG) accounts for 15–20% of all myasthenia gravis (MG) cases and is typically characterized by severe clinical manifestations and suboptimal ...